Insulet inks deal with Samsung to develop smartphone-controlled Omnipod

This article was originally published here

Insulet (NSDQ:PODD) said this week that it inked a deal with Samsung to develop an Omnipod insulin delivery system that would allow users to control their insulin pump therapy with a Galaxy smartphone.

If approved, the system would be the first of its kind, according to the Billerica, Mass.-based company.

Get the full story at our sister site, Drug Delivery Business News.

The post Insulet inks deal with Samsung to develop smartphone-controlled Omnipod appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply